Conjugated indole-imidazole derivatives displaying cytotoxicity against multidrug resistant cancer cell lines.
We report herein the SAR studies of a series of indole-imidazole compounds. that demonstrate substantial in vitro anti-proliferative activities against cancer cell lines, including multidrug resistance (MDR) phenotypes. The in vitro cytotoxic effects have been demonstrated across a wide array of tumor types, including hematologic and solid tumor cell lines of various origins (e.g., leukemia, breast, colon, and uterine).
James
David A
DA
Synta Pharmaceuticals, 45 Hartwell Ave, Lexington, MA 02421, USA.
Koya
Keizo
K
Li
Hao
H
Chen
Shoujun
S
Xia
Zhiqiang
Z
Ying
Weiwen
W
Wu
Yaming
Y
Sun
Lijun
L
D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D018432:Drug Resistance, Multiple; D006801:Humans; D007093:Imidazoles / Q000138:chemical synthesis* / Q000494:pharmacology; D007211:Indoles / Q000138:chemical synthesis* / Q000494:pharmacology; D020128:Inhibitory Concentration 50; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D007093:Imidazoles; D007211:Indoles